Medicare GLP-1 Bridge vs Part D: Which One Covers Your Prescription?

On Medicare, the reason a GLP-1 is prescribed decides who pays for it. Prescriptions for type 2 diabetes, cardiovascular risk reduction, sleep apnea or MASH go through your regular Part D plan. Prescriptions for weight management alone may qualify for the temporary Medicare GLP-1 Bridge, which charges $50 a month and started July 1, 2026. The two paths have different rules, different costs, and they count differently toward your yearly out-of-pocket cap.

Here's how it plays out. Two neighbors are at the same pharmacy picking up the same brand of pen. One pays $50 through the Bridge. The other pays their Part D plan's coinsurance. Nobody made a mistake. Their prescriptions were written for different reasons.

Why does Medicare have two pathways for GLP-1s?

By law, Medicare Part D can't cover drugs used specifically for weight loss, as KFF explains. Part D plans can cover GLP-1s for other approved uses, like type 2 diabetes. Once Wegovy gained a heart-risk indication and Zepbound gained a sleep apnea indication, those uses became coverable too.

The Medicare GLP-1 Bridge fills the weight-management gap for now. CMS describes it as a demonstration that runs "outside the Part D benefit's coverage and payment flow." It has its own central processor that handles prior authorization and claims, so your Part D plan isn't the one making the decision. CMS says the Bridge runs through December 31, 2027, and Bridge prior authorizations stay valid through that date unless you switch GLP-1s.

Bridge vs Part D at a glance

	Regular Part D plan	Medicare GLP-1 Bridge
What it's for	Diabetes, CV risk reduction, OSA, MASH and other covered uses	Weight management only, for eligible people
Drugs	Whatever's on your plan's formulary (e.g., Ozempic, Mounjaro, Rybelsus, Trulicity, Wegovy, Zepbound)	Wegovy (pen or tablet), Foundayo, Zepbound KwikPen only
Who approves	Your plan (its PA, ST, QL rules)	CMS's central processor
Your cost	Plan cost-sharing: 2026 deductible up to $615, then 25% coinsurance until the cap	$50 per one-month supply, no deductible
Counts toward the 2026 $2,100 out-of-pocket cap?	Yes	No
Extra Help (LIS) lowers it?	Yes, if you qualify	No
Manufacturer coupons?	No (federal program)	No
Questions and status	Your plan; Part D exceptions and appeals apply	1-800-MEDICARE for eligibility or PA status

For 2027, Medicare.gov lists a maximum Part D deductible of $700 and an out-of-pocket threshold of $2,400.

Six scenarios: which pathway applies?

These are made-up examples based on the CMS rules. They're not coverage decisions, and your prescriber and plan make the actual call.

1. Rosa: type 2 diabetes, Ozempic

Rosa takes Ozempic for type 2 diabetes. Her BMI is 36. Pathway: Part D. CMS says people with type 2 diabetes aren't eligible for the Bridge, even if they meet the BMI criteria, and even if their Part D plan doesn't cover a GLP-1 for diabetes. Her costs follow her plan's tier and count toward her $2,100 cap.

2. Frank: a past heart attack, Wegovy to lower heart risk

Frank had a heart attack, and his BMI is 29. His cardiologist prescribes Wegovy to reduce the risk of major adverse cardiovascular events. Pathway: Part D. CMS tells plans to route a GLP-1 prescribed for cardiovascular risk reduction to Part D, "even if weight reduction is also a purpose." See our SELECT trial explainer for where that indication comes from.

3. Linda: moderate-to-severe sleep apnea, Zepbound

Linda has moderate-to-severe obstructive sleep apnea and obesity. Pathway: Part D. OSA is one of the conditions that excludes someone from the Bridge, and Zepbound for OSA is a use Part D can cover. If her plan doesn't list it, she and her prescriber can ask the plan for a formulary exception. More on the indication in our tirzepatide and sleep apnea post.

4. Mike: BMI 37, no diabetes, weight management

Mike's prescriber wants to treat his obesity, and he has no diabetes, OSA or MASH. Pathway: the Bridge, if the prior authorization is approved. He'd pay $50 per monthly fill of Wegovy, Foundayo or the Zepbound KwikPen. Zepbound vials or single-dose pens aren't included.

5. Ann: BMI 28 with prediabetes

Ann has prediabetes and a BMI of 28. Pathway: the Bridge, if the prescription is for weight management. One criterion is a BMI of 27 or higher plus prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. Without one of those conditions, a BMI of 28 wouldn't qualify. The eligibility checklist covers every criterion.

6. Joe: already had a GLP-1 through Part D in 2026

Joe's Part D plan covered a GLP-1 for him earlier in 2026. Pathway: Part D for the rest of 2026. CMS says anyone who got a listed GLP-1 through Part D in calendar year 2026 can't use the Bridge in 2026. That includes Ozempic, Mounjaro, Wegovy, Zepbound, Rybelsus, Trulicity, Victoza, Saxenda and Foundayo. Medicare.gov says such people can keep getting their GLP-1 through their plan. CMS says the lookback rule for 2027 hasn't been decided.

Is $50 on the Bridge always cheaper than Part D?

Usually, but not always. Run the numbers:

• Bridge: $50 × 12 months = $600 a year. None of it counts toward your Part D cap.
• Part D: You pay your plan's cost-sharing, but every dollar counts toward the $2,100 cap for 2026. Once you hit the cap, covered Part D drugs cost $0 for the rest of the year.

Say you already take other expensive Part D drugs and reach the cap by spring. A GLP-1 covered under Part D would then cost nothing, while a Bridge GLP-1 would still cost $50 a month. In most cases, though, the reason for the prescription decides the pathway, not which one is cheaper. Medicare.gov also notes that Bridge copays don't show up on your Explanation of Benefits and can't be spread out with the Medicare Prescription Payment Plan. Keep your own receipts.

How do you find out which pathway you're on?

1. Ask your prescriber what diagnosis the prescription is written for. That's what routes it.
2. For Part D, look up the drug in your plan's formulary and check the tier and codes. Our guide on reading a formulary explains how.
3. For the Bridge, call 1-800-MEDICARE (TTY 1-877-486-2048) to check eligibility or prior authorization status. Approved people get a letter confirming coverage under the Bridge.
4. Write it down: the pathway, the approval date and how long it lasts. A dose change or a switch to a different GLP-1 can mean new paperwork. Logging your refills and dose changes in one place, whether that's a notebook or an app like GLPily, makes those calls easier.

Program details can change, especially for a demonstration program. Check the CMS and Medicare.gov pages before making a decision about costs. For the full program overview, read Medicare GLP-1 Bridge in 2026.

Common questions

Does the Medicare GLP-1 Bridge cover Ozempic or Mounjaro?

No. The Bridge covers Wegovy (pen or tablet), Foundayo and the Zepbound KwikPen. Ozempic and Mounjaro are diabetes medicines covered through regular Part D plans when they're on the plan's formulary.

Does the $50 Bridge copay count toward the $2,100 Part D out-of-pocket cap?

No. CMS says no part of the $50 copay counts toward your Part D true out-of-pocket costs. The Part D deductible doesn't apply, and Extra Help doesn't lower it.

If my Part D plan doesn't cover Zepbound for sleep apnea, can I use the Bridge instead?

No. CMS says people with moderate-to-severe OSA aren't eligible for the Bridge, even if their plan doesn't cover the drug. You and your prescriber can ask your Part D plan for a coverage exception and appeal if it's denied.

When does the Medicare GLP-1 Bridge end?

CMS says the Bridge started July 1, 2026, and was extended through December 31, 2027. Check the CMS page for later changes.